Since the first CAR-T cell product was approved by the FDA in 2017, five additional CAR-T cell products have reached the market, all of which target CD19 or BCMA. These products have gathered
14 approvals in different haematological malignancies and some of them have moved to earlier lines of therapy, expanding their target population. Moreover, earlier this year, lifileucel, a non-genetically modified tumour-infiltrating lymphocyte (TIL) therapy, became the first FDA-approved cell therapy product for a solid tumour (metastatic melanoma). Furthermore, an engineered cell therapy product, the T-cell-receptor (TCR)-based therapy afamitresgene autoleucel, may receive approval later this year for the treatment of advanced synovial sarcoma.
